To assess whether Src activation contributes to development of peritoneal fibrosis, 5 mg/kg of KX2-391, a highly selective Src inhibitor that is orally bioavailable and under clinical trials for tumors [25, 26], was administered immediately after CG injection at day 1 and then given daily for 21 days. The gene discussed is SRC; the disease is Peritoneal Fibrosis.